Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242615 | 0.91 | CYP4F2 (0.41) | CYP4F2CYP4A11BCHEACHEKCNA5 | |
| SCHEMBL24012964 | 0.91 | CYP4F2 (0.41) | CYP4F2CYP4A11BCHEACHEKCNA5 | |
| SCHEMBL30242527 | 0.85 | PLA2G2A (0.38) | CYP4F2CYP4A11BCHEACHEPLA2G2A | |
| SCHEMBL24013113 | 0.83 | CYP4F2 (0.52) | CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL27032051 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11BCHEACHEPLA2G2A | |
| SCHEMBL27032476 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11PLA2G2ARXRARXRB | |
| SCHEMBL24012869 | 0.82 | CYP4F2 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30242635 | 0.81 | L3MBTL1 (0.42) | CYP4F2CYP4A11EGFRMEN1KMT2A | |
| SCHEMBL26630588 | 0.81 | L3MBTL1 (0.42) | CYP4F2CYP4A11EGFRMEN1KMT2A | |
| SCHEMBL24012965 | 0.80 | MAOB (0.41) | CYP4F2CYP4A11BCHEACHEKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | CYP4F2 4675/4885CYP4A11 4178/4885BCHE 3597/4885 |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | CYP4F2 4470/4885CYP4A11 4478/4885BCHE 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.